Axovant Gene Therapies Announces Commencement of Public Offering
February 19 2020 - 4:02PM
Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today
announced that it has commenced an underwritten public offering of
its common shares and pre-funded warrants to purchase its common
shares. In connection with this offering, Axovant expects to grant
the underwriters a 30-day option to purchase up to an additional
15% of the aggregate number of common shares plus the common shares
underlying the pre-funded warrants in the offering on the same
terms and conditions. All of the common shares and pre-funded
warrants are being offered by Axovant.
SVB Leerink is acting as sole book-running manager for the
offering. The offering is subject to market conditions, and there
can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
A shelf registration statement relating to the securities
described above was filed with the Securities and Exchange
Commission (SEC), and was declared effective on January 13,
2017. A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on the SEC’s website,
located at www.sec.gov. Before you invest, you should read the
preliminary prospectus supplement and accompanying prospectus
together with other documents that Axovant has filed with the SEC
for more complete information about Axovant and the offering.
Copies of the preliminary prospectus supplement and accompanying
base prospectus related to the offering may be obtained, when
available, from SVB Leerink LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor Boston, MA,
02110, by telephone at 1-800-808-7525, ext. 6218, or by email
at syndicate@svbleerink.com.
This announcement is neither an offer to sell nor a solicitation
of an offer to buy any of these securities, and shall not
constitute an offer, solicitation, or sale in any jurisdiction in
which such offer, solicitation, or sale is unlawful.
About Axovant
Axovant Gene Therapies, part of the Roivant family of companies,
is a clinical-stage company focused on developing a pipeline of
innovative gene therapy product candidates for debilitating
neurological diseases. The company's current pipeline of gene
therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis
(including Tay-Sachs disease and Sandhoff disease), and Parkinson’s
disease. Axovant is focused on accelerating product candidates into
and through clinical trials with a team of experts in gene therapy
development and through external partnerships with leading gene
therapy organizations.
Contacts:
Investors and Analysts
David NassifAxovant Gene TherapiesChief Financial Officer(646)
677-6770
Media
Parag Meswani Axovant Gene Therapies (212) 547-2523
investors@axovant.com media@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jul 2023 to Jul 2024